The JI
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     
 


This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Lauritsen, J. P. H.
Right arrow Articles by Geisler, C.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Lauritsen, J. P. H.
Right arrow Articles by Geisler, C.
The Journal of Immunology, 1998, 161: 260-267.
Copyright © 1998 by The American Association of Immunologists

Two Distinct Pathways Exist for Down-Regulation of the TCR1

Jens Peter H. Lauritsen, Mette D. Christensen, Jes Dietrich, Jesper Kastrup, Niels Ødum and Carsten Geisler2

Institute of Medical Microbiology and Immunology, University of Copenhagen, The Panum Institute, Copenhagen, Denmark


    Abstract
 Top
 Abstract
 Introduction
 Materials and Methods
 Results
 Discussion
 References
 
TCR down-regulation plays an important role in modulating T cell responses both during T cell development and in mature T cells. Down-regulation of the TCR is induced by engagement of the TCR by specific ligands and/or by activation of protein kinase C (PKC). We report here that ligand- and PKC-induced TCR down-regulation is mediated by two distinct, independent mechanisms. Ligand-induced TCR down-regulation is dependent on the protein tyrosine kinases p56lck and p59fyn but independent of PKC and the CD3{gamma} leucine-based (L-based) internalization motif. In contrast, PKC-induced TCR down-regulation is dependent on the CD3{gamma} L-based internalization motif but independent of p56lck and p59fyn. Finally, our data indicate that in the absence of TCR ligation, TCR expression levels can be finely regulated via the CD3{gamma} L-based motif by the balance between PKC and serine/threonine protein phosphatase activities. Such a TCR ligation-independent regulation of TCR expression levels could probably be important in determining the activation threshold of T cells in their encounter with APC.


    Introduction
 Top
 Abstract
 Introduction
 Materials and Methods
 Results
 Discussion
 References
 
Dynamic regulation of TCR cell surface expression is probably an important mechanism allowing T cells to calibrate their responses to different levels of stimuli. Several studies have shown that TCR down-regulation occurs in response to MHC/peptide stimulation (1, 2, 3, 4, 5, 6), anti-TCR Ab binding (7, 8, 9), or to treatment of T cells with activators of protein kinase C (PKC)3 (10, 11, 12). The physiologic role of TCR down-regulation is still not fully known, and it is possible that regulation of TCR expression serves different purposes at different stages of T cell ontogeny. CD4+CD8+ thymocytes express low levels of TCR; however, when removed from the thymus and placed in suspension culture at 37°C TCR, expression is rapidly up-regulated. Several studies have indicated that a high level of p56lck activity is responsible for the low level of TCR expression in CD4+CD8+ thymocytes. Thus, inhibition of CD4-associated p56lck activity by injecting anti-CD4 mAb or culturing thymocytes in suspension at 37°C results in TCR up-regulation on CD4+CD8+ thymocytes (13, 14, 15); CD4+CD8+ thymocytes from MHC class II, p56lck, and CD45 knockout mice have high basal levels of TCR expression (16, 17, 18); and finally, CD4+CD8+ thymocytes from transgenic mice with a constitutive active form of p56lck express lower levels of TCR than CD4+CD8+ thymocytes from nontransgenic mice (19).

TCR down-regulation may also play a role in induction of tolerance. Transgenic models of peripheral nonresponsiveness have demonstrated that T cell tolerance can be maintained by down-regulation of the TCR (20, 21, 22, 23). In addition to the process of tolerance induction, TCR down-regulation has been observed during T cell activation, and it has been proposed that TCR down-regulation might be involved in T cell activation by allowing serial triggering of many TCR by few peptide-MHC complexes (3, 4, 24).

Although p56lck seems to play a central role in regulation of the TCR expression levels on CD4+CD8+ thymocytes, the role of p56lck in ligand-induced TCR down-regulation in mature T cells is not clear. In one study, TCR down-regulation caused by superantigens was not prevented by the protein tyrosine kinase (PTK) inhibitors genistein, tyrphostin, or herbimycin, and furthermore, superantigen-induced TCR down-regulation was observed in the p56lck deficient cell line J.CaM. The authors concluded that ligand-induced TCR down-regulation can occur in the absence of PTK activation including activation of p56lck (25). In contrast, a very recent paper found that ligand-induced TCR down-regulation is dependent on p56lck activation (26).

It is known that during physiologic T cell stimulation, PKC is activated (27) and CD3{gamma} becomes phosphorylated (28). The molecular mechanisms behind PKC-mediated TCR down-regulation have recently been characterized in detail. Thus, PKC-mediated TCR down-regulation is absolutely dependent on the CD3{gamma} leucine-based (L-based) (SDKQTLL) internalization motif and can be described as a two-step process: 1) recognition of the TCR subunit CD3{gamma} by PKC with subsequent phosphorylation of CD3{gamma} S126 (12), in which basic amino acids surrounding S126 are important (29); and 2) exposure of the CD3{gamma} L-based motif following S126 phosphorylation with subsequent binding of clathrin-coated vesicle adaptor proteins and internalization of the TCR (30). The role of PKC and the CD3{gamma} L-based motif in ligand-induced TCR down-regulation is still not clear. A recent study has indicated that phosphorylation of S126 in the CD3{gamma} L-based motif is not required for ligand-induced TCR down-regulation (25). However, another study has indicated that the cytoplasmic tail of CD3{gamma} is required for ligand-induced TCR down-regulation (31). Thus, it still remains an open question as to how and if ligand- and PKC-induced TCR down-regulation are interrelated.


    Materials and Methods
 Top
 Abstract
 Introduction
 Materials and Methods
 Results
 Discussion
 References
 
Cells, transfectants, and reagents

JGN, a TCR cell surface negative variant of the human T cell line Jurkat that synthesizes no CD3{gamma} was produced in our own laboratory (32). The transfectant JGN-S126V expresses CD3{gamma} with a serine 126 to valine mutation. Neither CD3{gamma} phosphorylation nor TCR down-regulation is seen in this transfectant following PKC activation (12). JGN-LLAA cells express CD3{gamma} with leucine 131 and 132 to alanine mutations. In this transfectant, CD3{gamma} is phosphorylated at S126 following PKC activation, but the TCR is not down-regulated (12). JGN-tP133 cells express CD3{gamma} truncated at proline 133. CD3{gamma} phosphorylation and TCR down-regulation is observed in this transfectant following PKC activation (12). JGN-tQ117 cells express a cytoplasmic tail-less CD3{gamma} truncated at glutamine 117 (33) and do not down-regulate the TCR subsequent to PKC activation. The Jurkat clones E6-1 (E6), J.CaM1.6 (J.CaM) (a p56lck-deficient variant of E6 (34)), J.45.01 (J.45) (a CD45-deficient variant of E6 (35)), and the Burkitt’s lymphoma cell line Raji were from American Type Culture Collection (Manassas, VA). Cells were cultured in RPMI 1640 medium supplemented with penicillin, 2 x 105 U/L (Leo Pharmaceutical Products, Ballerup, Denmark), streptomycin, 50 mg/L (Merck, Darmstadt, Germany), and 10% (v/v) FCS (Life Technologies, Paisley, U.K.) at 37°C in 5% CO2. The anti-TCR mAb F101.01 was produced in our own laboratory (36). Phycoerythrin (PE)-conjugated anti-CD3{epsilon} mAb UCHT1, FITC-conjugated anti-transferrin receptor (TfR) mAb, and FITC-conjugated anti-CD45 mAb were from PharMingen (San Diego, CA). The anti-phosphotyrosine mAb 4G10 was from United States Biochemicals (Lake Placid, NY). The FITC-conjugated goat anti-mouse Ig Ab was from Jackson ImmunoResearch (West Grove, PA). The phorbol ester phorbol 12,13-dibutyrate (PDB) was from Sigma Chemical (St. Louis, MO); the superantigen staphylococcal enterotoxin E (SEE) from Toxin Technology (Sarasota, FL); and the PKC inhibitor Ro 31-8220 was a kind gift from Dr. D. Bradshaw (Roche Research Centre, Welwyn Garden City, U.K.). Brefeldin A (BFA) was from Boehringer Mannheim (Mannheim, Germany), and the serine/threonine protein phosphatase inhibitor calyculin A was from Biomol (Plymouth Meeting, PA).

TCR down-regulation, phosphotyrosine blots, and measurement of endocytic rates

For TCR down-regulation, cells were adjusted to 1 x 106 cells per ml of medium and incubated at 37°C with various concentrations of PDB, the anti-TCR mAb F101.01, or Raji cells pulsed for 1 h with different concentrations of SEE. At the indicated time, cells were transferred to ice-cold PBS containing 2% FCS and 0.1% NaN3 and washed twice. The cells were stained directly with PE-conjugated anti-CD3{epsilon} and analyzed using a FACScalibur flow cytometer (Becton Dickinson, Mountain View, CA). In experiments using the anti-TCR mAb F101.01 for TCR down-regulation, TCR expression was measured by staining the cells with saturating amounts of F101.01 followed by FITC-conjugated goat anti-mouse Ig Ab to avoid false negative results, as F101.01 inhibits binding of anti-CD3 mAb and vice versa (36). Likewise, in experiments using the PKC inhibitor Ro 31-8220, TCR expression was measured by staining the cells with saturating amounts of F101.01 followed by FITC-conjugated goat anti-mouse Ig Ab, as Ro 31-8220 disturbs measurements of PE fluorescence. Mean fluorescence intensity (MFI) was recorded and used in the calculation of percentage anti-CD3/TCR binding: (MFI of treated cells)/(MFI of untreated cells) x 100%. For each construct, at least three independent clones were analyzed. Phosphotyrosine blots were performed as previously described (37). To determine the endocytic rate of the TCR, cells were incubated at a cell density of 2 x 105 cells per ml medium at 37°C or 4°C with PE-conjugated anti-CD3 mAb. At the indicated time, aliquots of cell suspension were washed in ice-cold PBS containing 2% FCS and 0.1% NaN3 and immediately treated with 300 µl 0.5 M NaCl, 0.5 M acetic acid, pH 2.2, for 10 s. The acid-resistant fluorescence of the cells (representing internalized anti-CD3 mAb) was measured in the FACScalibur. The percentage of internalized anti-CD3 mAb to cell surface-bound anti-CD3 mAb was subsequently calculated using the equation: ((HAR - CAR)/CT) x 100%, where HAR is the MFI of acid-treated cells incubated at 37°C, CAR is the MFI of acid-treated cells incubated at 4°C, and CT is the MFI of untreated cells incubated at 4°C.

Transfection

The plasmid pRep-lck, containing mouse p56lck cDNA (38), was transfected into J.CaM cells, and the plasmid pAW-HLCA, containing cDNA coding for the human 180 kDa isoform of CD45 (39), was transfected into J.45 cells. Transfections were performed using the Bio-Rad (Hercules, CA) Gene Pulser at a setting of 260 V, 960 µF with 40 µg of plasmid per 2 x 107 cells. After 3 to 4 wk of selection, hygromycin B (pRep-lck)- and G418 (pAW-HLCA)-resistant clones were expanded.


    Results
 Top
 Abstract
 Introduction
 Materials and Methods
 Results
 Discussion
 References
 
Ligand-induced TCR down-regulation is not dependent on the CD3{gamma} L-based internalization motif

To analyze whether ligand-induced TCR down-regulation was dependent on the CD3{gamma} L-based internalization motif, transfectants expressing either wild-type CD3{gamma} (JGN-WT) or CD3{gamma} with mutations in the L-based motif that completely abolish PKC-mediated TCR down-regulation (JGN-S126V and JGN-LLAA) (Fig. 1GoA) were incubated with the anti-TCR mAb F101.01, SEE-pulsed Raji cells, or the phorbol ester PDB. In contrast to PKC-mediated TCR down-regulation, ligand-induced TCR down-regulation following incubation with anti-TCR mAb or SEE-pulsed Raji cells was as efficient in JGN-S126V and JGN-LLAA cells as in JGN-WT cells (Fig. 1Go, B–D). This demonstrated that ligand-induced TCR down-regulation was not dependent on the presence of an intact CD3{gamma} L-based motif. In addition to the L-based motif, a tyrosine-based (Y-based) motif involved in receptor internalization and sorting has been described in the cytoplasmic tail of CD3{gamma} (40). To test whether this motif was required for ligand-induced TCR down-regulation, the transfectant JGN-tP133 that expresses a truncated CD3{gamma} lacking the Y-based motif, was analyzed. Ligand-induced TCR down-regulation was as efficient in JGN-tP133 cells as in JGN-WT cells, demonstrating that the Y-based motif of CD3{gamma} is not required for ligand-induced TCR internalization. Finally, to test whether a still unidentified motif in the CD3{gamma} cytoplasmic tail required for ligand-induced TCR down-regulation exists, the CD3{gamma} tail-less transfectant JGN-tQ117 was analyzed. Even JGN-tQ117 cells down-regulated the TCR as efficiently as JGN-WT cells following TCR ligation, demonstrating that the CD3{gamma} cytoplasmic tail, inclusive of the L- and Y-based sorting motifs, was dispensable for ligand-induced TCR down-regulation.



View larger version (46K):
[in this window]
[in a new window]
 
FIGURE 1. Ligand-induced TCR down-regulation is not dependent on the CD3{gamma} L-based internalization motif. A, Schematic representation of the amino acid sequences in the cytoplasmic tails of the CD3{gamma} chains expressed in the indicated cell lines. B, Cells were incubated with different concentrations of the anti-TCR mAb F101.01 for 1 h and TCR down-regulation was determined by staining with F101.01 and FITC-conjugated goat anti-mouse Ig Ab followed by flow cytometry comparing the MFI of F101.01-treated cells with the MFI of untreated cells. C, Cells were incubated with Raji cells prepulsed with different concentrations of SEE for 1 h, and TCR down-regulation was determined by staining with PE-conjugated anti-CD3{epsilon} mAb followed by flow cytometry comparing the MFI of Raji/SEE-treated cells with the MFI of untreated cells. D, Cells were incubated with different concentrations of the PKC activator PDB for 1 h, and TCR down-regulation was determined by staining with PE-conjugated anti-CD3{epsilon} mAb followed by flow cytometry comparing the MFI of PDB-treated cells with the MFI of untreated cells.

 
Ligand-induced TCR down-regulation is not dependent on PKC activity

The studies described above demonstrate that ligand-induced TCR down-regulation is independent of the CD3{gamma} L-based internalization motif. The TCR is associated with nonreceptor PTK that become activated following receptor ligation, which leads to activation of a range of intracellular molecules including PKC (27). As a consequence, PKC was most probably activated in all of the methods used to induce TCR down-regulation in the present study. Thus, the possibility existed that PKC activity was required for ligand-induced TCR down-regulation via a mechanism other than CD3{gamma} S126 phosphorylation. To test this hypothesis, TCR down-regulation was induced in JGN-WT cells by incubation with anti-TCR mAb, SEE-pulsed Raji cells, or PDB in the presence or absence of the PKC inhibitor Ro 31-8220. Ro 31-8220 clearly inhibited PDB-mediated TCR down-regulation, whereas ligand-induced TCR down-regulation was unaffected by the presence of the PKC inhibitor (Fig. 2Go). These results indicated that ligand-induced TCR down-regulation, in addition to being independent of the CD3{gamma} L-based motif, is independent of PKC activity.



View larger version (28K):
[in this window]
[in a new window]
 
FIGURE 2. Ligand-induced TCR-down-regulation is not dependent on PKC activity. JGN-WT and JGN-S126V cells were preincubated for 30 min in normal medium or in medium containing 3 µM Ro 31-8220 followed by treatment with the anti-TCR mAb F101.01 (1000 ng/ml), SEE (200 ng/ml)-pulsed Raji cells, PDB (111 nM), or pervanadate (vana) (10 µM) for 1 h. TCR down-regulation was determined by staining with F101.01 and FITC-conjugated goat anti-mouse Ig Ab followed by flow cytometry comparing the MFI of treated cells with the MFI of untreated cells.

 
Evidence for involvement of PTK in some steps of ligand-induced receptor internalization has been reported previously for the TCR (26, 41), the B cell receptor (42), and for receptors with intrinsic PTK activity (43, 44). Ligation of the TCR causes activation of nonreceptor PTK with subsequent protein tyrosine phosphorylation of a range of substrates (27). To analyze whether protein tyrosine phosphorylation per se could induce TCR down-regulation, JGN-WT cells were incubated with pervanadate. Pervanadate is a protein tyrosine phosphatase inhibitor that causes heavy protein tyrosine phosphorylation of several substrates including the {zeta} chain and activation of p56lck and p59fyn in Jurkat cells (45, 46, 47, 48). Treatment of JGN-WT cells with pervanadate induced strong protein tyrosine phosphorylation of several substrates including the {zeta} chain and an efficient down-regulation of the TCR (Fig. 2Go and data not shown). JGN-S126V cells down-regulated the TCR as efficiently as JGN-WT cells following pervanadate treatment and Ro 31-8220 did not inhibit pervanadate-induced TCR down-regulation in JGN-WT or JGN-S126V cells (Fig. 2Go). Thus, these experiments indicated that protein tyrosine phosphorylation per se is able to mediate TCR down-regulation independently of PKC and CD3{gamma} S126 phosphorylation.

Ligand-induced TCR down-regulation is dependent on protein tyrosine phosphorylation mediated by p56lck and p59fyn

To further examine the requirement of protein tyrosine phosphorylation in ligand- and PKC-induced TCR down-regulation, the cell lines J.CaM and J.45 were included in the study. J.CaM is a mutant of the Jurkat E6 line that lacks functional p56lck (38). J.45 is also a mutant of E6 and has markedly reduced amounts of CD45 resulting in an inability to activate p56lck and p59fyn following TCR stimulation (35). Both J.CaM and J.45 show very reduced protein tyrosine phosphorylation following TCR ligation (Refs. 35 and 38; and data not shown). Compared with E6 cells, anti-TCR-induced TCR down-regulation was markedly reduced in J.CaM cells and almost completely abolished in J.45 cells (Fig. 3GoA). SEE-induced TCR down-regulation was reduced in both variants compared with SEE-induced TCR down-regulation in E6 cells (Fig. 3GoB). In contrast, PKC-mediated TCR down-regulation was as efficient in both mutants as in the E6 cell line (Fig. 3GoC). These data indicate that both p56lck and p59fyn-mediated protein tyrosine phosphorylation is required for ligand-induced TCR down-regulation but is dispensable for PKC-mediated TCR down-regulation. To exclude the possibility that some unidentified mechanisms should be responsible for the reduced/abolished ligand-induced TCR down-regulation in J.CaM and J.45 cells, these mutants were transfected with p56lck and CD45, respectively. In the transfectants J.CaM-lck and J.45-CD45 TCR down-regulation and protein tyrosine phosphorylation patterns following anti-TCR stimulation were restored (Fig. 3GoD and data not shown). This indicated that the defect in ligand-induced TCR down-regulation in J.CaM and J.45 was directly correlated with the defect in p56lck and p59fyn-mediated protein tyrosine phosphorylation and was not caused by other defects.



View larger version (37K):
[in this window]
[in a new window]
 
FIGURE 3. Ligand-induced TCR down-regulation is dependent on protein tyrosine phosphorylation mediated by p56lck and p59fyn. A, Cells were incubated with different concentrations of the anti-TCR mAb F101.01 for 1 h, and TCR down-regulation was determined by staining with F101.01 and FITC-conjugated goat anti-mouse Ig Ab followed by flow cytometry comparing the MFI of F101.01-treated cells with the MFI of untreated cells. B, Cells were incubated with Raji cells prepulsed with SEE (2 ng/ml) for the indicated time, and TCR down-regulation was determined by staining with PE-conjugated anti-CD3{epsilon} mAb followed by flow cytometry comparing the MFI of Raji/SEE-treated cells with the MFI of untreated cells. C, Cells were incubated with different concentrations of PDB for 1 h, and TCR down-regulation was determined by staining with PE-conjugated anti-CD3{epsilon} mAb followed by flow cytometry comparing the MFI of PDB-treated cells with the MFI of untreated cells. D, E6 cells and the transfectants J.CaM-lck and J.45-CD45 were incubated with different concentrations of the anti-TCR mAb F101.01 for 1 h, and TCR down-regulation was determined by staining with F101.01 and FITC-conjugated goat anti-mouse Ig Ab followed by flow cytometry comparing the MFI of F101.01-treated cells with the MFI of untreated cells.

 
Regulation of TCR levels can be mediated via the CD3{gamma} L-based motif by the balance between PKC and serine/threonine protein phosphatase activities in the absence of TCR ligation

As the CD3{gamma} L-based motif was dispensable for ligand-induced TCR down-regulation, we speculated as to what role(s) this motif could play in TCR function. It may be suggested that in the absence of TCR ligation, TCR expression is regulated via the CD3{gamma} L-based motif by environmental factors such as cytokines influencing the balance between PKC and serine/threonine protein phosphatase activities (49, 50). Thus, tuning the balance in favor of PKC activity should result in activation of the CD3{gamma} L-based motif, leading to reduced levels of TCR expression, whereas tuning the balance in favor of serine/threonine protein phosphatase activity should result in inactivation of the CD3{gamma} L-based motif, leading to increased levels of TCR expression. Such a cytokine-mediated, TCR ligation-independent regulation of TCR expression levels could probably be important in determining the activation threshold of T cells in their encounter with APC (51).

We wanted to determine first whether different levels of PKC activity would result in different stable levels of TCR expression. Previous studies have demonstrated that PKC is activated by phorbol esters in a dose-dependent manner (52, 53). Up-regulation of PKC activity to different levels clearly influenced TCR expression in JGN-WT cells (Fig. 4GoA) but not in cells with a mutated CD3{gamma} L-based motif (data not shown). By varying the amount of PDB, new levels of TCR expression (between 80 and 30% of untreated cells) were obtained (Fig. 4GoA). Importantly, these new levels of TCR expression were stable following incubation with PDB for 30 to 60 min and correlated with the concentration of PDB. In agreement with other studies (Refs. 54 and 55; and J. Dietrich et al.4), we found that following PKC-mediated TCR internalization, the TCR was not degraded but was recycled back to the cell surface (data not shown). This indicated that different stable TCR expression levels were obtained by changing the endocytic rate of the TCR. To examine whether the reduced but stable levels of TCR expression obtained by up-regulation of PKC activity were maintained by an increased endocytic rate, TCR internalization was measured in untreated cells and in cells pretreated with PDB for 60 min. Although the concentration of anti-CD3 mAb used to measure the endocytic rate induced some TCR internalization, the endocytic rate of the TCR was clearly increased in PDB-pretreated JGN-WT cells as compared with untreated cells (Fig. 4GoB). In contrast, the endocytic rate of the TCR in JGN-LLAA cells was unaffected by the presence of PDB (Fig. 4GoB).



View larger version (24K):
[in this window]
[in a new window]
 
FIGURE 4. New stable levels of TCR expression can be obtained by altering PKC activity. A, JGN-WT cells were incubated with various concentration of PDB for the indicated periods, and TCR down-regulation was determined by staining with PE-conjugated anti-CD3{epsilon} mAb followed by flow cytometry comparing MFI of PDB-treated cells with the MFI of untreated cells. B, Cells were preincubated for 60 min at 37°C in normal medium or in medium containing 12 nM PDB. The endocytotic rates were then determined as described in Materials and Methods.

 
In general, a reduction in the exocytic rate of a recycling receptor will result in a decreased receptor expression correlating with the endocytic rate, i.e., receptors with high endocytic rates will be down-regulated faster than receptors with low endocytic rates following inhibition of exocytosis. On the assumption that a certain basal level of PKC activity influenced the activity of the CD3{gamma} L-based motif, the amount of recycling TCR in PDB-untreated cells should be higher in cells with an intact CD3{gamma} L-based motif than in transfectants with a mutated CD3{gamma} L-based motif. This implies that a reduction in exocytosis should result in a greater decrease in TCR expression in JGN-WT cells than in cells with a mutated CD3{gamma} L-based motif. The fungal metabolite BFA has been demonstrated to reduce the exocytic rate of the TfR with little or no effect on the endocytic rate (56). The TfR is a spontaneously recycling receptor with high endocytic and exocytic rates and was included as a control in the following experiments. Treatment of JGN-WT cells with BFA caused a down-regulation of TCR and TfR expression to stable levels of approximately 90 and 55%, respectively, as compared with untreated cells. In contrast, BFA treatment of cells with a disrupted CD3{gamma} L-based motif did not cause a reduction in TCR expression but only in TfR expression (Fig. 5Go, A and B). In JGN-WT cells, in which the endocytic rate was further increased by pretreatment with PDB for 60 min, the effect of BFA was even more obvious. BFA treatment of cells pretreated with PDB thus resulted in a TCR down-regulation to 66% as compared with 90% for nonpretreated cells (Fig. 5GoC). These analyses indicated that TCR expression levels in cells with an intact CD3{gamma} L-based motif were determined by the degree of PKC activity, and furthermore, that a basal PKC-mediated phosphorylation of the CD3{gamma} L-based motif existed. In addition, a basal serine/threonine protein phosphatase-mediated dephosphorylation of the CD3{gamma} L-based motif probably also existed in the cells, as incubation of JGN-WT cells with the serine/threonine protein phosphatase inhibitor calyculin A caused a down-regulation of the TCR to new stable levels, whereas TCR expression levels on JGN-LLAA cells were unaffected by this inhibitor (Fig. 5GoD and data not shown).



View larger version (40K):
[in this window]
[in a new window]
 
FIGURE 5. Spontaneous PKC and serine/threonine protein phosphatase activities influence the activity of the CD3{gamma} L-based motif. A and B, Cells were incubated with BFA (5 µg/ml) for the indicated periods. TCR and TfR down-regulation were simultaneously determined by double staining with PE-conjugated anti-CD3{epsilon} (A) and FITC-conjugated anti-TfR (B) mAb followed by flow cytometry comparing the MFI of BFA-treated cells with the MFI of untreated cells. C, JGN-WT cells were preincubated for 60 min in normal medium or in medium containing 12 nM PDB and then treated with BFA (5 µg/ml) for the indicated periods. TCR down-regulation was determined by staining with PE-conjugated anti-CD3{epsilon} mAb followed by flow cytometry comparing the MFI of BFA-treated cells with the MFI of untreated cells. D, Cells were incubated with various concentrations of calyculin A for 1 h. TCR expression was then determined by staining with PE-conjugated anti-CD3{epsilon} mAb followed by flow cytometry comparing the MFI of calyculin A-treated cells with the MFI of untreated cells.

 
Taken together, these experiments indicated that in the absence of TCR ligation, TCR expression levels could be tightly regulated via the CD3{gamma} L-based motif by the balance between PKC and serine/threonine protein phosphatase activities.


    Discussion
 Top
 Abstract
 Introduction
 Materials and Methods
 Results
 Discussion
 References
 
This study demonstrates that two different pathways exist for regulation of TCR expression levels. One pathway is mediated by the balance between PKC and serine/threonine protein phosphatase activities, is strictly dependent on the CD3{gamma} L-based motif but independent of p56lck and p59fyn, and leads to TCR recycling (54, 55).4 The other pathway is induced by TCR ligation, is dependent on p56lck- and p59fyn-mediated protein tyrosine phosphorylation but independent of the CD3{gamma} L-based motif and PKC, and leads to TCR degradation (26, 57, 58). Both p56lck and p59fyn probably play a role in ligand-induced TCR down-regulation. Thus, although markedly reduced, the anti-TCR mAb-induced TCR down-regulation was not abolished in J.CaM cells that lack functional p56lck but express p59fyn (35, 38). In contrast, anti-TCR mAb-induced TCR down-regulation was almost completely abolished in J.45 cells, which are unable to activate both p59fyn and p56lck following TCR ligation (35). A role of p56lck in TCR down-regulation is in agreement with previous studies describing involvement of p56lck in TCR down-regulation in CD4+CD8+ thymocytes (13, 14, 15) and with a very recent study demonstrating that a constitutive, active form of p56lck induces rapid internalization of the TCR and that p56lck is required for anti-TCR mAb induced TCR down-regulation (26). In contrast, another study found that ligand-induced TCR down-regulation did occur in the absence of p56lck (25). In that study, SEE-induced TCR down-regulation in J.CaM cells was found to be comparable with that of wild-type cells; furthermore, the PTK inhibitors genistein, tyrphostin, and herbimycin did not inhibit SEE-induced TCR down-regulation. Anti-TCR mAb-induced TCR down-regulation was not examined in that study. We found that although anti-TCR mAb-induced TCR-down-regulation was markedly reduced in J.CaM cells and almost completely abolished in J.45 cells, SEE-induced TCR-down-regulation was reduced to a lesser degree in these cells. It is possible that SEE-induced TCR-down-regulation is mediated by protein tyrosine phosphorylation independently of p56lck, caused by signaling through several costimulatory molecules, as recently described (59). The exact substrate(s) needed to be tyrosine phosphorylated for ligand-induced TCR down-regulation to take place still remains to be identified. Furthermore, the exact mechanisms behind ligand-induced TCR down-regulation remain to be determined. Several, not mutually exclusive mechanisms can be proposed. 1) Ligand-mediated protein tyrosine phosphorylation induces a conformational change that exposes a Y-based internalization motif for clathrin-coated vesicle adaptor protein binding. In line with this proposal, a direct interaction between adaptor proteins and Y-based internalization motifs has been described for several receptors (60, 61, 62, 63, 64, 65, 66). The present study demonstrated that the Y-based internalization motif in CD3{gamma} (40) is not required for ligand-induced TCR down-regulation, as ligand-induced TCR down-regulation was intact in JGN-tP133 and JGN-tQ117 cells lacking the Y-based motif of CD3{gamma}. 2) Ligand-mediated protein tyrosine phosphorylation induces a conformational change that exposes the DxxxLL internalization motif of CD3{gamma} and CD3{delta} for adaptor protein binding. In line with this proposal, we have recently described both the CD3{gamma} and CD3{delta} L-based motifs as having the potential to function as internalization motifs and have shown that adaptor proteins can bind to such motifs (30). The present study does not rule out this possibility, as all of the transfectants analyzed contained an intact CD3{delta} DxxxLL motif. Furthermore, this proposal is supported by a recent study describing the inability to down-regulate the TCR after ligand binding in a T cell variant with deletion of the cytoplasmic tails of both CD3{gamma} and CD3{delta} (31). 3) Ligand-mediated protein tyrosine phosphorylation leads to ubiquitination of the TCR with subsequent endocytosis. This suggestion is supported by the observation that the TCR is ubiquitinated, in a PTK-dependent way, following ligation (47, 67) and that receptor ubiquitination can lead to internalization (68, 69, 70). 4) Ligand-mediated tyrosine phosphorylation of the {zeta} chain creates docking sites for src homology domain 2-containing proteins leading to recruitment of several other molecules including the adaptor molecule Grb2 (71), which might play a role in receptor internalization (72).

It is known that during physiologic T cell stimulation, PKC is activated (27) and CD3{gamma} becomes phosphorylated (28). In the present study, the PKC inhibitor Ro 31-8220 did not inhibit ligand-induced TCR down-regulation, indicating that non-PKC-dependent pathways are dominant during ligand-induced TCR down-regulation. Alternatively, TCR ligation may activate PKC isoforms distinct from those stimulated by PDB, and only those induced by PDB promote TCR internalization. Treatment of cells with PDB is likely to have pleiotropic effects, including the potential activation of some serine/threonine protein phosphatases, which could complicate the interpretation of our data. However, we find that treatment of Jurkat cells with 111 nM of PDB for 1.5 h does not influence the activity of PP1 and PP2A, which are the phosphatases most likely involved in dephosphorylation of CD3{gamma} (Lauritsen et al., unpublished data).

The present study strongly indicates that the CD3{gamma} L-based motif is not required in ligand-mediated TCR down-regulation. However, the CD3{gamma} L-based motif has been extremely conserved during evolution and is even found in the common CD3{gamma}/{delta} chain from the chicken (73) and the frog (GenBank accession number U78290), indicating that the motif must play some important physiologic role(s). One role of the CD3{gamma} L-based motif could be in TCR quality control, by targeting incompletely assembled TCR complexes to the endosomes/lysosomes for degradation, as previously described (30). In line with this possibility, it has been demonstrated that TCR complexes lacking the {zeta} chain are mainly transported to the late endosomes/lysosomes for degradation (74). These observations suggest that {zeta} normally cover the L-based TCR internalization motifs, which could explain why only completely assembled TCR are allowed to be normally expressed at the T cell surface. Another role of the CD3{gamma} L-based motif, as suggested by the present study, could be in finely tuning the TCR expression levels as a response to environmental factors such as cytokines that influence the activities of PKC and serine/threonine protein phosphatases. Further studies are in progress to evaluate these potential roles of the CD3{gamma} L-based motif.


    Acknowledgments
 
We thank Dr. A. Weiss for plasmid pREP-lck and Dr. G. A. Koretzky for plasmid pAW-HLCA. The technical help of Bodil L. Nielsen is gratefully acknowledged.


    Footnotes
 
1 This work was supported by The Danish Cancer Society, The Novo Nordisk Foundation, The Danish Medical Research Council, The Danish Natural Science Research Council, Director Ib Henriksens Foundation, Gerda and Aage Haensch’s Foundation, and Director Leo Nielsen and wife Karen Magrethe Nielsen Foundation for Medical Basic Research. J.P.H.L. and M.D.C. were recipients of scholarships from The Danish Cancer Society and The Danish Medical Research Council, respectively. J.D. and J.K. were recipients of Ph.D. scholarships from the University of Copenhagen. C.G. and N.Ø. are members of The Biotechnology Center for Cellular Communication. Back

2 Address correspondence and reprint requests to Dr. Carsten Geisler, Institute of Medical Microbiology and Immunology, University of Copenhagen, The Panum Institute, Building 18.3, Blegdamsvej 3C, DK-2200 Copenhagen, Denmark. E-mail address: Back

3 Abbreviations used in this paper: PKC, protein kinase C; PTK, protein tyrosine kinase; PE, phycoerythrin; TfR, transferrin receptor; PDB, phorbol 12,13-dibutyrate; SEE, staphylococcal enterotoxin E; BFA, brefeldin A; MFI, mean fluorescence intensity; L-based, leucine-based; Y-based, tyrosine-based. Back

4 J. Dietrich, T. Backstrom, J. P. H. Lauritsen, J. Kastrup, M. D. Christensen, F. von Bulow, E. Palmer, and C. Geisler. The phosphorylation state of CD3{gamma} influences T cell responsiveness and controls T cell receptor cycling. Manuscript submitted for publication. Back

Received for publication December 26, 1997. Accepted for publication March 6, 1998.


    References
 Top
 Abstract
 Introduction
 Materials and Methods
 Results
 Discussion
 References
 

  1. Lamb, J. R., B. J. Skidmore, N. Green, J. M. Chiller, M. Feldmann. 1983. Induction of tolerance in influenza virus-immune T lymphocyte clones with synthetic peptides of influenza hemagglutinin. J. Exp. Med. 157:1434.[Abstract/Free Full Text]
  2. Zanders, E. D., J. R. Lamb, M. Feldman, N. Green, P. C. L. Beverley. 1983. Tolerance of T-cell clones is associated with membrane antigen changes. Nature 303:625.[Medline]
  3. Valitutti, S., S. Muller, M. Cella, E. Padovan, A. Lanzavecchia. 1995. Serial triggering of many T-cell receptors by a few peptide-MHC complexes. Nature 375:148.[Medline]
  4. Valitutti, S., S. Muller, M. Dessing, A. Lanzavecchia. 1996. Different responses are elicited in cytotoxic T lymphocytes by different levels of T cell receptor occupancy. J. Exp. Med. 183:1917.[Abstract/Free Full Text]
  5. Cai, Z., H. Kishimoto, A. Brunmark, M. R. Jackson, P. A. Peterson, J. Sprent. 1997. Requirements for peptide-induced T cell receptor downregulation on naive CD8+ T cells. J. Exp. Med. 185:641.[Abstract/Free Full Text]
  6. La Face, D. M., C. Couture, K. Anderson, G. Shih, J. Alexander, A. Sette, T. Mustelin, A. Altman, H. M. Grey. 1997. Differential T cell signaling induced by antagonist peptide-MHC complexes and the associated phenotypic responses. J. Immunol. 158:2057.[Abstract]
  7. Reinherz, E. L., S. Meuer, K. A. Fitzgerald, R. E. Hussey, H. Levine, S. F. Schlossman. 1982. Antigen recognition by human T lymphocytes is linked to surface expression of the T3 molecular complex. Cell 30:735.[Medline]
  8. Telerman, A., R. B. Amson, F. Romasco, J. Wybran, P. Galand, R. Mosselmans. 1987. Internalization of human T lymphocyte receptors. Eur. J. Immunol. 17:991.[Medline]
  9. Boyer, C., N. Auphan, F. Luton, J.-M. Malburet, M. Barad, J.-P. Bizozzero, H. Reggio, A.-M. Schmitt-Verhulst. 1991. T cell receptor/CD3 complex internalization following activation of a cytolytic T cell clone: evidence for a protein kinase C-independent staurosporine-sensitive step. Eur. J. Immunol. 21:1623.[Medline]
  10. Ando, I., G. Hariri, D. Wallace, P. Beverley. 1985. Tumor promoter phorbol esters induce unresponsiveness to antigen and expression of interleukin 2 receptor on T cells. Eur. J. Immunol. 15:196.[Medline]
  11. Cantrell, D. A., A. A. Davies, M. J. Crumpton. 1985. Activators of protein kinase C down-regulate and phosphorylate the T3/T-cell antigen receptor complex of human T lymphocytes. Proc. Natl. Acad. Sci. USA 82:8158.[Abstract/Free Full Text]
  12. Dietrich, J., X. Hou, A.-M. K. Wegener, C. Geisler. 1994. CD3{gamma} contains a phosphoserine-dependent di-leucine motif involved in down-regulation of the T cell receptor. EMBO J. 13:2156.[Medline]
  13. McCarthy, S. A., A. M. Kruisbeek, I. K. Uppenkamp, S. O. Sharrow, A. Singer. 1988. Engagement of the CD4 molecule influences cell surface expression of the T-cell receptor on thymocytes. Nature 336:76.[Medline]
  14. Nakayama, T., C. H. June, T. I. Munitz, M. Sheard, S. A. McCarthy, S. O. Sharrow, L. E. Samelson, A. Singer. 1990. Inhibition of T cell receptor expression and function in immature CD4+CD8+ cells by CD4. Science 249:1558.[Abstract/Free Full Text]
  15. Wiest, D. L., L. Yuan, J. Jefferson, P. Benveniste, M. Tsokos, R. D. Klausner, L. H. Glimcher, L. E. Samelson, A. Singer. 1993. Regulation of T cell receptor expression in immature CD4+CD8+ thymocytes by p56lck tyrosine kinase: basis for differential signaling by CD4 and CD8 in immature thymocytes expressing both coreceptor molecules. J. Exp. Med. 178:1701.[Abstract/Free Full Text]
  16. Cosgrove, D., D. Gray, A. Dierich, J. Kaufman, M. Lemeur, C. Benoist, D. Mathis. 1991. Mice lacking MHC class II molecules. Cell 66:1051.[Medline]
  17. Molina, T. J., K. Kishihara, D. P. Siderovski, E. W. van, A. Narendran, E. Timms, A. Wakeham, C. J. Paige, K. U. Hartmann, A. Veillette. 1992. Profound block in thymocyte development in mice lacking p56lck. Nature 357:161.[Medline]
  18. Stone, J. D., L. A. Conroy, K. F. Byth, R. A. Hederer, S. Howlett, Y. Takemoto, N. Holmes, D. R. Alexander. 1997. Aberrant TCR-mediated signaling in CD45-null thymocytes involves dysfunctional regulation of Lck, Fyn, TCR-zeta, and ZAP-70. J. Immunol. 158:5773.[Abstract]
  19. Ericsson, P. O., H. S. Teh. 1995. The protein tyrosine kinase p56lck regulates TCR expression and T cell selection. Int. Immunol. 7:617.[Abstract/Free Full Text]
  20. Schonrich, G., U. Kalinke, F. Momburg, M. Malissen, A. M. Schmitt Verhulst, B. Malissen, G. J. Hammerling, B. Arnold. 1991. Down-regulation of T cell receptors on self-reactive T cells as a novel mechanism for extrathymic tolerance induction. Cell 65:293.[Medline]
  21. Rocha, B., H. von Boehmer. 1991. Peripheral selection of the T cell repertoire. Science 251:1225.[Abstract/Free Full Text]
  22. Ferber, I., G. Schonrich, J. Schenkel, A. L. Mellor, G. J. Hammerling, Arnold, and B. 1994. Levels of peripheral T cell tolerance induced by different doses of tolerogen. Science. 263:674.
  23. Tafuri, A., J. Alferink, P. Moller, G. J. Hammerling, B. Arnold. 1995. T cell awareness of paternal alloantigens during pregnancy. Science 270:630.[Abstract/Free Full Text]
  24. Valitutti, S., A. Lanzavecchia. 1997. Serial triggering of TCRs: a basis for the sensitivity and specificity of antigen recognition. Immunol. Today 18:299.[Medline]
  25. Salio, M., S. Valitutti, A. Lanzavecchia. 1997. Agonist-induced T cell receptor down-regulation: molecular requirements and dissociation from T cell activation. Eur. J. Immunol. 27:1769.[Medline]
  26. D’Oro, U., M. S. Vacchio, A. M. Weissman, J. D. Ashwell. 1997. Activation of the Lck tyrosine kinase targets cell surface T cell antigen receptors for lysosomal degradation. Immunity 7:619.[Medline]
  27. Weiss, A., D. R. Littman. 1994. Signal transduction by lymphocyte antigen receptors. Cell 76:263.[Medline]
  28. Cantrell, D., A. A. Davies, M. Londei, M. Feldman, M. J. Crumpton. 1987. Association of phosphorylation of the T3 antigen with immune activation of T lymphocytes. Nature 325:540.[Medline]
  29. Dietrich, J., X. Hou, A.-M. K. Wegener, L. O. Pedersen, N. Odum, C. Geisler. 1996. Molecular characterization of the di-leucine based internalization motif of the T cell receptor. J. Biol. Chem. 271:11441.[Abstract/Free Full Text]
  30. Dietrich, J., J. Kastrup, B. L. Nielsen, N. Odum, C. Geisler. 1997. Regulation and function of the CD3{gamma} DxxxLL motif: a binding site for adaptor protein-1 and adaptor protein-2 in vitro. J. Cell. Biol. 138:271.[Abstract/Free Full Text]
  31. Luton, F., M. Buferne, V. Legendre, E. Chauvert, C. Boyer, A.-M. Schmitt-Verhulst. 1997. Role of CD3{gamma} and CD3{delta} cytoplasmic domains in cytolytic T lymphocyte functions and TCR/CD3 down-modulation. J. Immunol. 158:4162.[Abstract]
  32. Geisler, C.. 1992. Failure to synthesize the CD3-{gamma} chain: consequences for T cell antigen receptor assembly, processing, and expression. J. Immunol. 148:2437.[Abstract]
  33. Dietrich, J., A. Neisig, X. Hou, A.-M. K. Wegener, M. Gajhede, C. Geisler. 1996. Role of CD3{gamma} in T cell receptor assembly. J. Cell. Biol. 132:299.[Abstract/Free Full Text]
  34. Goldsmith, M. A., A. Weiss. 1987. Isolation and characterization of a T-lymphocyte somatic mutant with altered signal transduction by the antigen receptor. Proc. Natl. Acad. Sci. USA 84:6879.[Abstract/Free Full Text]
  35. Koretzky, G. A., J. Picus, T. Schultz, A. Weiss. 1991. Tyrosine phosphatase CD45 is required for T-cell antigen receptor and CD2-mediated activation of a protein tyrosine kinase and interleukin 2 production. Proc. Natl. Acad. Sci. USA 88:2037.[Abstract/Free Full Text]
  36. Geisler, C., T. Plesner, G. Pallesen, K. Skjodt, N. Odum, J. K. Larsen. 1988. Characterization and expression of the human T cell receptor-T3 complex by monoclonal antibody F101.01. Scand. J. Immunol. 27:685.[Medline]
  37. Hou, X., J. Dietrich, N. Odum, C. Geisler. 1996. The cytoplasmic tail of Fc{gamma}RIIIA{alpha} is involved in signalling by the low affinity receptor for IgG. J. Biol. Chem. 271:22815.[Abstract/Free Full Text]
  38. Straus, D. B., A. Weiss. 1992. Genetic evidence for the involvement of the lck tyrosine kinase in signal transduction through the T cell antigen receptor. Cell 70:585.[Medline]
  39. Koretzky, G. A., M. A. Kohmetscher, T. Kadleck, A. Weiss. 1992. Restoration of T cell receptor-mediated signal transduction by transfection of CD45 cDNA into a CD45-deficient variant of the Jurkat T cell line. J. Immunol. 149:1138.[Abstract]
  40. Letourneur, F., R. D. Klausner. 1992. A novel di-leucine motif and a tyrosine-based motif independently mediate lysosomal targeting and endocytosis of CD3 chains. Cell 69:1143.[Medline]
  41. Luton, F., M. Buferne, J. Davoust, A. M. Schmitt-Verhulst, C. Boyer. 1994. Evidence for protein tyrosine kinase involvement in ligand- induced TCR/CD3 internalization and surface redistribution. J. Immunol. 153:63.[Abstract]
  42. Pure, E., L. Tardelli. 1992. Tyrosine phosphorylation is required for ligand-induced internalization of the antigen receptor on B lymphocytes. Proc. Natl. Acad. Sci. USA 89:114.[Abstract/Free Full Text]
  43. Lamaze, C., S. L. Schmid. 1995. Recruitment of epidermal growth factor receptors into coated pits requires their activated tyrosine kinase. J. Cell. Biol. 129:47.[Abstract/Free Full Text]
  44. Carpentier, J. L., J. P. Paccaud, J. Backer, A. Gilbert, L. Orci, C. R. Kahn, and J. c. t. B. , and J. Baecker. 1993. Two steps of insulin receptor internalization depend on different domains of the beta-subunit. J. Cell. Biol. 122:1243.
  45. Secrist, J. P., L. A. Burns, L. Karnitz, G. A. Koretzky, R. T. Abraham. 1993. Stimulatory effects of the protein tyrosine phosphatase inhibitor, pervanadate, on T-cell activation events. J. Biol. Chem. 268:5886.[Abstract/Free Full Text]
  46. Imbert, V., J. F. Peyron, F. D. Farahi, B. Mari, P. Auberger, B. Rossi. 1994. Induction of tyrosine phosphorylation and T-cell activation by vanadate peroxide, an inhibitor of protein tyrosine phosphatases. Biochem. J. 297:163.
  47. Cenciarelli, C., Jr K. G. Wilhelm, A. Guo, A. M. Weissman. 1996. T cell antigen receptor ubiquitination is a consequence of receptor-mediated tyrosine kinase activation. J. Biol. Chem. 271:8709.[Abstract/Free Full Text]
  48. Imbert, V., D. Farahifar, P. Auberger, D. Mary, B. Rossi, J. F. Peyron. 1996. Stimulation of the T-cell antigen receptor-CD3 complex signaling pathway by the tyrosine phosphatase inhibitor pervanadate is mediated by inhibition of CD45: evidence for two interconnected Lck/Fyn- or zap-70-dependent signaling pathways. J. Inflamm. 46:65.[Medline]
  49. Kolesnick, R., D. W. Golde. 1994. The sphingomyelin pathway in tumor necrosis factor and interleukin-1 signaling. Cell 77:325.[Medline]
  50. Hannun, Y. A.. 1994. The sphingomyelin cycle and the second messenger function of ceramide. J. Biol. Chem. 269:3125.[Free Full Text]
  51. Viola, A., A. Lanzavecchia. 1996. T cell activation determined by T cell receptor number and tunable thresholds. Science 273:104.[Abstract]
  52. Castagna, M., Y. Takai, K. Kaibuchi, K. Sano, U. Kikkawa, Y. Nishizuka. 1982. Direct activation of calcium-activated, phospholipid-dependent protein kinase by tumor-promoting phorbol esters. J. Biol. Chem. 257:7847.[Abstract/Free Full Text]
  53. Yamanishi, J., Y. Takai, K. Kaibuchi, K. Sano, M. Castagna, Y. Nishizuka. 1983. Synergistic functions of phorbol ester and calcium in serotonin release from human platelets. Biochem. Biophys. Res. Commun. 112:778.[Medline]
  54. Krangel, M. S.. 1987. Endocytosis and recycling of the T3-T cell receptor complex: the role of T3 phosphorylation. J. Exp. Med. 165:1141.[Abstract/Free Full Text]
  55. Minami, Y., L. E. Samelson, R. D. Klausner. 1987. Internalization and cycling of the T cell antigen receptor. J. Biol. Chem. 262:13342.[Abstract/Free Full Text]
  56. Schonhorn, J. E., M. Wessling-Resnick. 1994. Brefeldin A down-regulates the transferrin receptor in K562 cells. Mol. Cell. Biochem. 135:159.[Medline]
  57. Valitutti, S., S. Muller, M. Salio, A. Lanzavecchia. 1997. Degradation of T cell receptor (TCR)-CD3-zeta complexes after antigenic stimulation. J. Exp. Med. 185:1859.[Abstract/Free Full Text]
  58. Luton, F., V. Legendre, J. P. Gorvel, A. M. Schmitt-Verhulst, C. Boyer. 1997. Tyrosine and serine protein kinase activities associated with ligand-induced internalized TCR/CD3 complexes. J. Immunol. 158:3140.[Abstract]
  59. Yamasaki, S., M. Tachibana, N. Shinohara, M. Iwashima. 1997. Lck-independent triggering of T-cell antigen receptor signal transduction by staphylococcal enterotoxins. J. Biol. Chem. 272:14787.[Abstract/Free Full Text]
  60. Pearse, B. M. F.. 1988. Receptors compete for adaptors found in plasma membrane coated pits. EMBO J. 7:3331.[Medline]
  61. Glickman, J. N., E. Conibear, B. M. Pearse. 1989. Specificity of binding of clathrin adaptors to signals on the mannose-6-phosphate/insulin-like growth factor II receptor. EMBO J. 8:1041.[Medline]
  62. Beltzer, J. P., M. Spiess. 1991. In vitro binding of the asialoglycoprotein receptor to the beta adaptin of plasma membrane-coated vesicles. EMBO J. 10:3735.[Medline]
  63. Sosa, M. A., B. Schmidt, K. von Figura, A. Hille-Rehfeld. 1993. In vitro binding of plasma membrane-coated vesicle adaptors to the cytoplasmic domain of lysosomal acid phosphatase. J. Biol. Chem. 268:12537.[Abstract/Free Full Text]
  64. Sorkin, A., G. Carpenter. 1993. Interaction of activated EGF receptors with coated pit adaptins. Science 261:612.[Abstract/Free Full Text]
  65. Nesterov, A., R. C. Kurten, G. N. Gill. 1995. Association of epidermal growth factor receptors with coated pit adaptins via a tyrosine phosphorylation-regulated mechanism. J. Biol. Chem. 270:6320.[Abstract/Free Full Text]
  66. Ohno, H., J. Stewart, M. C. Fournier, H. Bosshart, I. Rhee, S. Miyatake, T. Saito, A. Gallusser, T. Kirchhausen, J. S. Bonifacino. 1995. Interaction of tyrosine-based sorting signals with clathrin- associated proteins. Science 269:1872.[Abstract/Free Full Text]
  67. Cenciarelli, C., D. Hou, K. C. Hsu, B. L. Rellahan, D. L. Wiest, H. T. Smith, VA Fried, A. M. Weissman. 1992. Activation-induced ubiquitination of the T cell antigen receptor. Science 257:795.[Abstract/Free Full Text]
  68. Strous, G. J., P. van Kerkhof, R. Govers, A. Ciechanover, A. L. Schwartz. 1996. The ubiquitin conjugation system is required for ligand-induced endocytosis and degradation of the growth hormone receptor. EMBO J. 15:3806.[Medline]
  69. Hicke, L., H. Riezman. 1996. Ubiquitination of a yeast plasma membrane receptor signals its ligand-stimulated endocytosis. Cell 84:277.[Medline]
  70. Weissman, A. M.. 1997. Regulating protein degradation by ubiquitination. Immunol. Today 18:189.[Medline]
  71. Koretzky, G. A.. 1997. The role of Grb2-associated proteins in T-cell activation. Immunol. Today 18:401.[Medline]
  72. Wang, Z., M. F. Moran. 1996. Requirement for the adapter protein GRB2 in EGF receptor endocytosis. Science 272:1935.[Abstract]
  73. Bernot, A., C. Auffray. 1991. Primary structure and ontogeny of an avian CD3 transcript. Proc. Natl. Acad. Sci. USA 88:2550.[Abstract/Free Full Text]
  74. Sussman, J. J., J. S. Bonifacino, J. Lippincott-Schwartz, A. M. Weissman, T. Saito, R. D. Klausner, J. D. Ashwell. 1988. Failure to synthesize the T cell CD3-{zeta} chain: structure and function of a partial T cell receptor complex. Cell 52:85.[Medline]



This article has been cited by other articles:


Home page
J. Immunol.Home page
C. M. Bonefeld, M. Haks, B. Nielsen, M. von Essen, L. Boding, A. K. Hansen, J. M. Larsen, N. Odum, P. Krimpenfort, A. Kruisbeek, et al.
TCR Down-Regulation Controls Virus-Specific CD8+ T Cell Responses
J. Immunol., December 1, 2008; 181(11): 7786 - 7799.
[Abstract] [Full Text] [PDF]


Home page
J. Immunol.Home page
S. P. Hickman, J. Yang, R. M. Thomas, A. D. Wells, and L. A. Turka
Defective Activation of Protein Kinase C and Ras-ERK Pathways Limits IL-2 Production and Proliferation by CD4+CD25+ Regulatory T Cells
J. Immunol., August 15, 2006; 177(4): 2186 - 2194.
[Abstract] [Full Text] [PDF]


Home page
J. Immunol.Home page
M. von Essen, M. W. Nielsen, C. M. Bonefeld, L. Boding, J. M. Larsen, M. Leitges, G. Baier, N. Odum, and C. Geisler
Protein Kinase C (PKC){alpha} and PKC{theta} Are the Major PKC Isotypes Involved in TCR Down-Regulation.
J. Immunol., June 15, 2006; 176(12): 7502 - 7510.
[Abstract] [Full Text] [PDF]


Home page
J. Immunol.Home page
S. Davanture, J. Leignadier, P. Milani, P. Soubeyran, B. Malissen, M. Malissen, A.-M. Schmitt-Verhulst, and C. Boyer
Selective Defect in Antigen-Induced TCR Internalization at the Immune Synapse of CD8 T Cells Bearing the ZAP-70(Y292F) Mutation
J. Immunol., September 1, 2005; 175(5): 3140 - 3149.
[Abstract] [Full Text] [PDF]


Home page
J. Immunol.Home page
M. von Essen, C. M. Bonefeld, V. Siersma, A. B. Rasmussen, J. P. H. Lauritsen, B. L. Nielsen, and C. Geisler
Constitutive and Ligand-Induced TCR Degradation
J. Immunol., July 1, 2004; 173(1): 384 - 393.
[Abstract] [Full Text] [PDF]


Home page
JEMHome page
V. L. Crotzer, A. S. Mabardy, A. Weiss, and F. M. Brodsky
T Cell Receptor Engagement Leads to Phosphorylation of Clathrin Heavy Chain during Receptor Internalization
J. Exp. Med., April 5, 2004; 199(7): 981 - 991.
[Abstract] [Full Text] [PDF]


Home page
J. Immunol.Home page
G. Criado and J. Madrenas
Superantigen Stimulation Reveals the Contribution of Lck to Negative Regulation of T Cell Activation
J. Immunol., January 1, 2004; 172(1): 222 - 230.
[Abstract] [Full Text] [PDF]


Home page
J. Immunol.Home page
C. M. Bonefeld, A. B. Rasmussen, J. P. H. Lauritsen, M. von Essen, N. Odum, P. S. Andersen, and C. Geisler
TCR Comodulation of Nonengaged TCR Takes Place by a Protein Kinase C and CD3{gamma} Di-Leucine-Based Motif-Dependent Mechanism
J. Immunol., September 15, 2003; 171(6): 3003 - 3009.
[Abstract] [Full Text] [PDF]


Home page
J. Immunol.Home page
P. S. Torres, A. Alcover, D. A. Zapata, J. Arnaud, A. Pacheco, J. M. Martin-Fernandez, E. M. Villasevil, O. Sanal, and J. R. Regueiro
TCR Dynamics in Human Mature T Lymphocytes Lacking CD3{gamma}
J. Immunol., June 15, 2003; 170(12): 5947 - 5955.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
B. M. Badran, S. M. Wolinsky, A. Burny, and K. E. Willard-Gallo
Identification of Three NFAT Binding Motifs in the 5'-Upstream Region of the Human CD3gamma Gene That Differentially Bind NFATc1, NFATc2, and NF-kappa B p50
J. Biol. Chem., November 27, 2002; 277(49): 47136 - 47148.
[Abstract] [Full Text] [PDF]


Home page
Int ImmunolHome page
P. S. Torres, D. A. Zapata, A. Pacheco-Castro, J. L. Rodriguez-Fernandez, C. Cabanas, and J. R. Regueiro
Contribution of CD3{gamma} to TCR regulation and signaling in human mature T lymphocytes
Int. Immunol., November 1, 2002; 14(11): 1357 - 1367.
[Abstract] [Full Text] [PDF]


Home page
J. Immunol.Home page
C. Dumont, N. Blanchard, V. Di Bartolo, N. Lezot, E. Dufour, S. Jauliac, and C. Hivroz
TCR/CD3 Down-Modulation and {zeta} Degradation Are Regulated by ZAP-70
J. Immunol., August 15, 2002; 169(4): 1705 - 1712.
[Abstract] [Full Text] [PDF]


Home page
J. Immunol.Home page
J. Dietrich, C. Menne, J. P. H. Lauritsen, M. von Essen, A. B. Rasmussen, N. Odum, and C. Geisler
Ligand-Induced TCR Down-Regulation Is Not Dependent on Constitutive TCR Cycling
J. Immunol., June 1, 2002; 168(11): 5434 - 5440.
[Abstract] [Full Text] [PDF]


Home page
J. Immunol.Home page
R. Zaru, T. O. Cameron, L. J. Stern, S. Muller, and S. Valitutti
TCR Engagement and Triggering in the Absence of Large-Scale Molecular Segregation at the T Cell-APC Contact Site
J. Immunol., May 1, 2002; 168(9): 4287 - 4291.
[Abstract] [Full Text] [PDF]


Home page
J. Immunol.Home page
M. von Essen, C. Menne, B. L. Nielsen, J. P. H. Lauritsen, J. Dietrich, P. S. Andersen, K. Karjalainen, N. Odum, and C. Geisler
The CD3{gamma} Leucine-Based Receptor-Sorting Motif Is Required for Efficient Ligand-Mediated TCR Down-Regulation
J. Immunol., May 1, 2002; 168(9): 4519 - 4523.
[Abstract] [Full Text] [PDF]


Home page
J. Immunol.Home page
M. D. Puente Navazo, D. Valmori, and C. Ruegg
The Alternatively Spliced Domain TnFnIII A1A2 of the Extracellular Matrix Protein Tenascin-C Suppresses Activation-Induced T Lymphocyte Proliferation and Cytokine Production
J. Immunol., December 1, 2001; 167(11): 6431 - 6440.
[Abstract] [Full Text] [PDF]


Home page
J. Immunol.Home page
B. Barbeau, G. A. Robichaud, J.-F. Fortin, and M. J. Tremblay
Negative Regulation of the NFAT1 Factor by CD45: Implication in HIV-1 Long Terminal Repeat Activation
J. Immunol., September 1, 2001; 167(5): 2700 - 2713.
[Abstract] [Full Text] [PDF]


Home page
BloodHome page
S. Krishnan, V. G. Warke, M. P. Nambiar, H. K. Wong, G. C. Tsokos, and D. L. Farber
Generation and biochemical analysis of human effector CD4 T cells: alterations in tyrosine phosphorylation and loss of CD3{zeta} expression
Blood, June 15, 2001; 97(12): 3851 - 3859.
[Abstract] [Full Text] [PDF]


Home page
JEMHome page
H. Kirchgessner, J. Dietrich, J. Scherer, P. Isomaki, V. Korinek, I. Hilgert, E. Bruyns, A. Leo, A. P. Cope, and B. Schraven
The Transmembrane Adaptor Protein TRIM Regulates T Cell Receptor (TCR) Expression and TCR-mediated Signaling via an Association with the TCR {zeta} Chain
J. Exp. Med., June 4, 2001; 193(11): 1269 - 1284.
[Abstract] [Full Text] [PDF]


Home page
J. Immunol.Home page
J. Dietrich, M. Cella, and M. Colonna
Ig-Like Transcript 2 (ILT2)/Leukocyte Ig-Like Receptor 1 (LIR1) Inhibits TCR Signaling and Actin Cytoskeleton Reorganization
J. Immunol., February 15, 2001; 166(4): 2514 - 2521.
[Abstract] [Full Text] [PDF]


Home page
J. Immunol.Home page
M. C. Haks, T. A. Cordaro, J. H. N. van den Brakel, J. B. A. G. Haanen, E. F. R. de Vries, J. Borst, P. Krimpenfort, and A. M. Kruisbeek
A Redundant Role of the CD3{{gamma}}-Immunoreceptor Tyrosine-Based Activation Motif in Mature T Cell Function
J. Immunol., February 15, 2001; 166(4): 2576 - 2588.
[Abstract] [Full Text] [PDF]


Home page
J. Immunol.Home page
C. Menne, J. P. H. Lauritsen, J. Dietrich, J. Kastrup, A.-M. K. Wegener, N. Odum, and C. Geisler
Ceramide-Induced TCR Up-Regulation
J. Immunol., September 15, 2000; 165(6): 3065 - 3072.
[Abstract] [Full Text] [PDF]


Home page
J. Immunol.Home page
A. Qadri, C. G. Radu, J. Thatte, P. Cianga, B. T. Ober, R. J. Ober, and E. S. Ward
A Role for the Region Encompassing the c'' Strand of a TCR V{alpha} Domain in T Cell Activation Events
J. Immunol., July 15, 2000; 165(2): 820 - 829.
[Abstract] [Full Text] [PDF]


Home page
Int ImmunolHome page
A. G. Schrum, A. D. Wells, and L. A. Turka
Enhanced surface TCR replenishment mediated by CD28 leads to greater TCR engagement during primary stimulation
Int. Immunol., June 1, 2000; 12(6): 833 - 842.
[Abstract] [Full Text] [PDF]


Home page
J. Virol.Home page
L. Bouhdoud, P. Villain, A. Merzouki, M. Arella, and C. Couture
T-Cell Receptor-Mediated Anergy of a Human Immunodeficiency Virus (HIV) gp120-Specific CD4+ Cytotoxic T-Cell Clone, Induced by a Natural HIV Type 1 Variant Peptide
J. Virol., March 1, 2000; 74(5): 2121 - 2130.
[Abstract] [Full Text]


Home page
Mol. Cell. Biol.Home page
J. E. M. van Leeuwen, P. K. Paik, and L. E. Samelson
The Oncogenic 70Z Cbl Mutation Blocks the Phosphotyrosine Binding Domain-Dependent Negative Regulation of ZAP-70 by c-Cbl in Jurkat T Cells
Mol. Cell. Biol., October 1, 1999; 19(10): 6652 - 6664.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
N. Bronstein-Sitton, L. Wang, L. Cohen, and M. Baniyash
Expression of the T Cell Antigen Receptor zeta Chain following Activation Is Controlled at Distinct Checkpoints. IMPLICATIONS FOR CELL SURFACE RECEPTOR DOWN-MODULATION AND RE-EXPRESSION
J. Biol. Chem., August 13, 1999; 274(33): 23659 - 23665.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
B. Fernandez, M. P. Czech, and H. Meisner
Role of Protein Kinase C in Signal Attenuation following T Cell Receptor Engagement
J. Biol. Chem., July 16, 1999; 274(29): 20244 - 20250.
[Abstract] [Full Text] [PDF]


Home page
J. Immunol.Home page
D. Penna, S. Muller, F. Martinon, S. Demotz, M. Iwashima, and S. Valitutti
Degradation of ZAP-70 Following Antigenic Stimulation in Human T Lymphocytes: Role of Calpain Proteolytic Pathway
J. Immunol., July 1, 1999; 163(1): 50 - 56.
[Abstract] [Full Text] [PDF]


Home page
J. Immunol.Home page
A. N. Vallejo, J. C. Brandes, C. M. Weyand, and J. J. Goronzy
Modulation of CD28 Expression: Distinct Regulatory Pathways During Activation and Replicative Senescence
J. Immunol., June 1, 1999; 162(11): 6572 - 6579.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
J. Dietrich, T. Backstrom, J. P. H. Lauritsen, J. Kastrup, M. D. Christensen, F. von Bulow, E. Palmer, and C. Geisler
The Phosphorylation State of CD3gamma Influences T Cell Responsiveness and Controls T Cell Receptor Cycling
J. Biol. Chem., September 11, 1998; 273(37): 24232 - 24238.
[Abstract] [Full Text] [PDF]


This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Lauritsen, J. P. H.
Right arrow Articles by Geisler, C.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Lauritsen, J. P. H.
Right arrow Articles by Geisler, C.


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS